Arrowhead Pharmaceuticals, Inc. beat EPS estimates 25% of the time across 16 reported quarters (4 beats, 12 misses), averaging -44.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q3 FY26 | $-1.23 | $-1.36 | -10.6% | Miss | Q3 FY26 call |
| Q2 FY26 | $-1.18 | $-0.93 | +21.2% | Beat | |
| Q1 FY26 | not reported | $0.22 | not reported | not reported | |
| Q4 FY25 | not reported | $-0.18 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | $-0.94 | $-1.26 | -34.0% | Miss | |
| Q2 FY25 | not reported | $2.75 | not reported | not reported | |
| Q1 FY25 | not reported | $-1.39 | not reported | not reported | |
| Q4 FY24 | $-0.63 | $-1.38 | -119.0% | Miss | |
| Q3 FY24 | $-0.58 | $-1.38 | -137.9% | Miss | |
| Q2 FY24 | not reported | $-1.02 | not reported | not reported | |
| Q1 FY24 | $-0.78 | $-1.24 | -59.0% | Miss | |
| Q4 FY23 | $-0.70 | $-1.03 | -47.1% | Miss |
Back to ARWR overview · ARWR holders · ARWR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.